1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - The slow resumption of tin mines in Myanmar and the easing of Sino-US economic and trade negotiations support tin prices. The expectation of future interest rate cuts and the halt of balance - sheet reduction by the Fed, along with the initial agreement in Sino - US economic and trade negotiations, suggest that the resumption of tin mines in Myanmar may not change the tight supply - demand situation. The Shanghai tin price is expected to be cautiously bullish. Investors are advised to build long positions after price pullbacks, paying attention to support and resistance levels [3]. - The negative basis and monthly spread of Shanghai tin are due to high tin prices suppressing downstream demand with only rigid procurement. Given the Fed's future policies and the slow resumption of tin mines in Myanmar, investors are advised to focus on short - term, light - position, low - buying arbitrage opportunities for the Shanghai tin basis. For LME tin, the positive (0 - 3) and (3 - 15) contract spreads are in a reasonable range, and it is recommended to temporarily wait and see for arbitrage opportunities [9][10]. 3. Summary by Directory 3.1 First Part: Spread and Inventory Situation - Shanghai tin basis is negative and at a relatively low level, and the monthly spread is negative and basically within a reasonable range. LME tin (0 - 3) and (3 - 15) contract spreads are positive and in a reasonable range, and the Shanghai - London tin price ratio is at the 50% quantile of the past five years [9][10]. - The inventory of refined tin on the Shanghai Futures Exchange decreased compared to last week; the social inventory of tin ingots in China decreased compared to last week; the inventory of refined tin on the London Metal Exchange increased compared to last week; the total inventory of refined tin at home and abroad decreased compared to last week [12]. 3.2 Second Part: Mid - upstream Supply Situation - The daily processing fee of domestic tin concentrates is oscillating downward, indicating a tight supply expectation of domestic tin mines. The production (import) volume of domestic tin mines in October increased (increased) month - on - month. The production volume of recycled tin in China in October may increase month - on - month [19][21][24]. - The capacity utilization rate of refined tin in China increased compared to last week. The production (inventory) volume of refined tin in China in October increased (decreased) month - on - month, and the import volume may increase month - on - month [26][28][29]. 3.3 Third Part: Downstream Demand Situation - The daily processing fee of photovoltaic solder strips decreased month - on - month, which may lead to an increase in the capacity utilization rate (inventory) of tin solder in China in October. The import (export) volume of solder strips in China in October may decrease (decrease) month - on - month [35][38]. - The production volume of tin - plated sheets in China in October may increase month - on - month, while the import and export volumes may decrease month - on - month. The capacity utilization rate of lead - acid batteries in China increased compared to last week [41][43][46].

Group 1 - A new company, Henan Jiuzhoutong Medical Equipment Co., Ltd., has been established with a registered capital of 10 million RMB [1] - The legal representative of the company is Li Wa [1] - The business scope includes the sale of Class I and Class II medical devices, as well as the rental of Class I medical equipment [1] Group 2 - The company is jointly owned by Jiuzhoutong Medical Equipment Group Co., Ltd. and Henan Beijia Enterprise Management Consulting Co., Ltd. [1]

Market Overview - The pharmaceutical commercial sector increased by 0.32% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Jianfa Zhixin (301584) closed at 39.29, up 10.18% with a trading volume of 315,400 shares and a transaction value of 1.142 billion [1] - Run Da Medical (603108) closed at 15.30, up 3.66% with a trading volume of 180,900 shares and a transaction value of 274 million [1] - Other notable performers include Huaren Health (301408) up 2.28%, and Saili Medical (603716) up 1.98% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 6.1445 million from institutional investors, while retail investors saw a net inflow of 56.1279 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors increased their positions [2] Individual Stock Capital Flow - Run Da Medical saw a significant net outflow of 49.9539 million from institutional investors, indicating a bearish sentiment [3] - Conversely, Jiuzhoutong (866000) had a net inflow of 16.7641 million from institutional investors, suggesting positive interest [3] - Other stocks like Nanjing Medical (600713) and Huaren Health (301408) also showed varying degrees of net inflows and outflows from different investor categories [3]

Core Viewpoint - 九州通's stock performance on October 23 showed no change, with a trading volume of 116 million yuan, indicating a stable market position despite fluctuations in financing activities [1] Financing Summary - On October 23, 九州通 had a financing buy-in amount of 9.31 million yuan and a financing repayment of 16.99 million yuan, resulting in a net financing outflow of 7.68 million yuan [1] - The total financing and securities lending balance for 九州通 as of October 23 was 721 million yuan, with the financing balance at 714 million yuan, accounting for 2.83% of the circulating market value, which is below the 30th percentile of the past year [1] - In terms of securities lending, 九州通 repaid 181,700 shares and sold 11,000 shares on October 23, with a selling amount of 55,100 yuan, while the remaining securities lending volume was 1.37 million shares, with a balance of 6.88 million yuan, exceeding the 90th percentile of the past year [1] Business Overview - 九州通, established on March 9, 1999, and listed on November 2, 2010, is based in Wuhan, Hubei Province, and operates in six main business areas: digital pharmaceutical distribution and supply chain, general brand promotion, pharmaceutical manufacturing and OEM, retail and franchise, digital logistics and supply chain solutions, and healthcare and technology value-added services [1] - The revenue composition of 九州通's main business includes: distribution segment 95.94%, industrial segment 1.96%, retail segment 1.84%, healthcare segment 0.17%, and other segments 0.08% [1] Financial Performance - As of June 30, 九州通 reported a total of 41,700 shareholders, a decrease of 12.92% from the previous period, with an average of 120,824 circulating shares per shareholder, an increase of 14.84% [2] - For the first half of 2025, 九州通 achieved an operating income of 81.11 billion yuan, a year-on-year increase of 5.10%, and a net profit attributable to shareholders of 1.45 billion yuan, reflecting a year-on-year growth of 19.70% [2] Dividend Information - 九州通 has cumulatively distributed dividends of 5.27 billion yuan since its A-share listing, with 2.91 billion yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh largest circulating shareholder of 九州通, holding 90.25 million shares, an increase of 8.74 million shares from the previous period [3]

Core Insights - The annual report released by Wuhan Enterprise Federation and Wuhan Entrepreneur Association highlights the significant growth and transformation of Wuhan's economy, with the total assets of the top 100 enterprises reaching 6.39 trillion yuan, a year-on-year increase of 10.1% [3][5]. Group 1: Enterprise Structure and Rankings - The number of private enterprises in the top 100 reached 50, surpassing state-owned enterprises for the first time, which numbered 48 [3][5]. - The top 20 enterprises are predominantly state-owned, holding 70% of the positions, indicating their continued influence in key sectors [3][5]. - China State Construction Engineering Corporation ranked first in the comprehensive top 100, followed by Dongfeng Motor Corporation and Zhuoer Zhili Group [13][15]. Group 2: Financial Performance - The revenue threshold for entering the top 100 was set at 4.738 billion yuan, slightly higher than the previous year [7]. - Eight enterprises achieved "billion-level" revenue, while the number of "hundred-billion-level" enterprises increased from 53 to 56 [7]. - The total profit of the comprehensive top 100 enterprises reached 69.957 billion yuan, with 83 enterprises reporting profits and 46 showing positive profit growth [7]. Group 3: Innovation and R&D - A total of 74 enterprises in the top 100 invested in R&D, with total R&D expenditure amounting to 60.424 billion yuan [9][11]. - Private enterprises showed a significant increase in R&D investment, growing by 54.26% year-on-year, outpacing revenue and profit growth [11]. - The number of enterprises with overseas revenue reached 40, generating a total of 189.224 billion yuan from international markets, a year-on-year increase of 57.76% [11]. Group 4: Industry Trends - The structure of the top enterprises is shifting, with an increase in service sector companies and a decrease in construction firms, reflecting a transition from investment-driven to innovation-driven growth [13]. - The report indicates a strong performance in sectors such as "optical, chip, screen, terminal, and network" and logistics, particularly among large state-owned enterprises [9].

九州通医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 证券代码：600998 证券简称：九州通 公告编号：临 2025-072 | | 被担保人名称 | | 广西九州通医药有限公司、广东九州通 | | --- | --- | --- | --- | | | | 医药有限公司等 | 家子公司 51 | | | 本次担保金额 | 万元 345,350.00 | | | 担保对象 | 实际为其提供的担保余额 | 1,218,734.00 | 万元 | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额 | 0.00 | | | --- | --- | --- | | （万元） | | | | 截至本公告日上市公司及其 | | | | 控股子公司对外担保总额 | 2,895,749.72 | ...

Report Information - Report Title: Non-ferrous Metals Weekly - Tin [1] - Date: October 21, 2025 [2] - Author: Wang Wenhu [2] - Contact: 021 - 51801878 [2] Investment Rating - Not provided in the report Core View - The uncertainty of China - US tariff negotiations weighs on tin prices, but the expectation of the Fed's future interest rate cuts and halt of balance - sheet reduction, along with the slow resumption of tin mines in Wa State, Myanmar, is unlikely to change the tight supply - demand situation. The Shanghai tin price is expected to be weak first and then strong. Investors are advised to mainly buy on price dips, paying attention to support and resistance levels [3]. Summary by Directory Part 1: Spread and Inventory Situation - The basis of Shanghai tin is positive and the monthly spread is negative, both within a reasonable range. Due to the Fed's future interest rate cut and halt of balance - sheet reduction expectations and the slow resumption of tin mines in Wa State, Myanmar, investors are advised to wait and see for arbitrage opportunities [7][9] - The (0 - 3) contract spread of LME tin is negative and the (3 - 15) contract spread is positive, both within a reasonable range. The Shanghai - London tin price ratio is below the 50% quantile of the past five years. Due to the Fed's expectations and the decreasing inventory of refined tin in LME, investors are advised to wait and see for arbitrage opportunities [10] - The inventory of refined tin in SHFE decreased compared with last week; the social inventory of tin ingots in China decreased compared with last week; the inventory of refined tin in LME increased compared with last week; the total inventory of refined tin at home and abroad decreased compared with last week [12] Part 2: Mid - upstream Supply Situation - The daily processing fee of domestic tin concentrate is oscillating downward, indicating a tight supply expectation of domestic tin mines [18][19] - The production (import) volume of Chinese tin mines in October increased (increased) month - on - month. Factors include the resumption of mines in Myanmar, Indonesia's mine policies, and the situation in other countries [21][23] - The production volume of Chinese recycled tin in October increased month - on - month [24][25] - The capacity utilization rate of Chinese refined tin increased compared with last week. The production (inventory) volume of Chinese refined tin in October increased (decreased) month - on - month [26][28] - The import volume of Chinese refined tin in October may increase month - on - month due to the production plans of foreign mines and export forecasts [29][31] Part 3: Downstream Demand Situation - The daily processing fee of photovoltaic solder strips decreased month - on - month, which may lead to an increase in the capacity utilization rate (inventory) of Chinese tin solder in October [35] - The import (export) volume of Chinese solder strips in October may decrease month - on - month [38][40] - The production (import, export) volume of Chinese tin - plated sheets in October may increase (decrease, decrease) month - on - month [41][43] - The capacity utilization rate of Chinese lead - acid batteries increased compared with last week. As tin is an important additive in lead - acid batteries, this may affect tin demand [44][46]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

Core Insights - The report indicates a significant rise in the strength of private enterprises in Wuhan, surpassing state-owned enterprises in the number of companies listed in the top 100 rankings for the first time [1] Group 1: R&D Investment - Private enterprises in Wuhan have increased their R&D investment by 54.26% compared to the previous year, significantly outpacing revenue and profit growth [2] - The rise in R&D investment has led to a notable increase in the proportion of invention patents and participation in industry standard formulation [2] - TCL Huaxing's collaboration with Xiaomi on the "Miao Xiang Back Screen" for the Xiaomi 17 Pro series exemplifies the technological advancements being pursued by local companies [2] Group 2: International Expansion - 40 of the top enterprises in Wuhan have begun to expand internationally, transitioning from initial market entry to establishing a local presence [3] - Renfu Pharmaceutical Group has invested in modern pharmaceutical factories in Mali and Ethiopia, resulting in a price reduction of over 30% for certain medications [3] - Longfei Optical Fiber Cable Co., Ltd. has successfully laid the world's first 7-core optical fiber submarine experimental cable, showcasing its technological capabilities on a global scale [3] Group 3: Industry Structure Optimization - The industrial structure of Wuhan's top enterprises is continuously optimizing, with emerging industries becoming key drivers of high-quality development [4] - The integration of AI in logistics by Jiuzhoutong Pharmaceutical Group has significantly enhanced operational efficiency, with an investment of 146 million yuan leading to substantial revenue [4] - Midea Group's investment in smart manufacturing equipment has resulted in over 50% automation in production, demonstrating the impact of technological upgrades [4]